SCHEMBL14830598

SCHEMBL14830598

CCCCC[C](C)CCC(C)(C)C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES2 O00748 5/20 0.39
CES1 P23141 5/20 0.39
AKR1B1 P15121 1/20 0.37
FAAH O00519 2/20 0.37
GPR84 Q9NQS5 7/20 0.36
PPARG P37231 7/20 0.36
PPARD Q03181 7/20 0.36
PPARA Q07869 7/20 0.36
HDAC11 Q96DB2 5/20 0.36
TSHR P16473 4/20 0.36
PTPN1 P18031 3/20 0.36
ALDH1A1 P00352 2/20 0.36
TLR2 O60603 2/20 0.36
TDP1 Q9NUW8 2/20 0.36
FABP4 P15090 2/20 0.36
SLC22A6 Q4U2R8 1/20 0.36
SLC22A8 Q8TCC7 1/20 0.36
MEN1 O00255 1/20 0.36
ESR1 P03372 1/20 0.36
ALOX15 P16050 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22401652 0.82 CES2 (0.53) CES2CES1AKR1B1GPR84PPARG
SCHEMBL14798823 0.79 CES2 (0.55) CES2CES1GPR84PPARGPPARD
SCHEMBL11172049 0.79 CES2 (0.55) CES2CES1GPR84PPARGPPARD
SCHEMBL4036124 0.79 CES2 (0.55) CES2CES1GPR84PPARGPPARD
SCHEMBL5134029 0.79 CES2 (0.55) CES2CES1GPR84PPARGPPARD
SCHEMBL16712189 0.79 CES2 (0.55) CES2CES1GPR84PPARGPPARD
SCHEMBL247451 0.79 CES2 (0.55) CES2CES1GPR84PPARGPPARD
SCHEMBL8675151 0.79 CES2 (0.55) CES2CES1GPR84PPARGPPARD
SCHEMBL2186772 0.79 CES2 (0.55) CES2CES1GPR84PPARGPPARD
SCHEMBL9487785 0.79 CES2 (0.55) CES2CES1GPR84PPARGPPARD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024052871-A1 NOVEL RUTHENIUM COMPLEXES, METHOD OF THEIR SYNTHESIS, INTERMEDIATE COMPOUNDS USED IN THIS METHOD, METHOD OF THEIR SYNTHESIS AND USE OF NOVEL RUTHENIUM COMPLEXES IN OLEFIN METATHESIS REACTIONS UNIWERSYTET WARSZAWSKI (PL) 2024-03-14 WO disclosed
US-20230295215-A1 NOVEL MRNA 5'-END CAP ANALOGS MODIFIED WITHIN PHOSPHATE RESIDUES, RNA MOLECULE INCORPORATING THE SAME, USES THEREOF AND METHOD OF SYNTHESIZING RNA MOLECULE OR PEPTIDE UNIWERSYTET WARSZAWSKI (PL) 2023-09-21 US disclosed
US-20230130423-A1 NOVEL MRNA 5'-END CAP ANALOGS, RNA MOLECULE INCORPORATING THE SAME, USES THEREOF AND METHOD OF SYNTHESIZING RNA MOLECULE OR PEPTIDE UNIWERSYTET WARSZAWSKI (PL) 2023-04-27 US disclosed
EP-4103578-A1 NOVEL MRNA 5'-END CAP ANALOGS MODIFIED WITHIN PHOSPHATE RESIDUES, RNA MOLECULE INCORPORATING THE SAME, USES THEREOF AND METHOD OF SYNTHESIZING RNA MOLECULE OR PEPTIDE Uniwersytet Warszawski (PL) 2022-12-21 EP disclosed
WO-2021162566-A1 NOVEL MRNA 5'-END CAP ANALOGS MODIFIED WITHIN PHOSPHATE RESIDUES, RNA MOLECULE INCORPORATING THE SAME, USES THEREOF AND METHOD OF SYNTHESIZING RNA MOLECULE OR PEPTIDE UNIWERSYTET WARSZAWSKI (PL) 2021-08-19 WO disclosed
EP-3820609-A1 <SMALLCAPS/>? ? ?N? ? ? ? ?USE OF-CHELATING RUTHENIUM COMPLEXES IN THE METATHESIS REACTION Apeiron Synthesis S.A. (PL) 2021-05-19 EP disclosed
EP-3356379-A1 PROCESS FOR PRODUCING RUTHENIUM COMPLEXES AND INTERMEDIATES THEREOF AND THEIR USE IN OLEFIN METATHESIS Apeiron Synthesis S.A. (PL) 2018-08-08 EP disclosed
EP-3294747-A1 RUTHENIUM COMPLEXES, METHOD OF PRODUCING THEM, AND THEIR USE Uniwersytet Warszawski (PL) 2018-03-21 EP disclosed
WO-2016092424-A1 RUTHENIUM COMPLEXES, METHOD OF PRODUCING THEM, AND THEIR USE UNIWERSYTET WARSZAWSKI (PL) 2016-06-16 WO disclosed
EP-2760581-A1 RUTHENIUM OR OSMIUM COMPLEX, METHOD FOR ITS PREPARATION AND USE THEREOF Instytut Chemii Organicznej Polskiej Akademii Nauk (PL) 2014-08-06 EP disclosed
WO-2013046108-A1 RUTHENIUM OR OSMIUM COMPLEX, METHOD FOR ITS PREPARATION AND USE THEREOF Instytut Chemii Organicznej Polskiej Akademii Nauk (PL) 2013-04-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230130423-A1 NOVEL MRNA 5'-END CAP ANALOGS, RNA MOLECULE INCORPORATING THE SAME, USES THEREOF AND METHOD OF SYNTHESIZING RNA MOLECULE OR PEPTIDE RNGTT, RNMT, NSUN3 CES2 4003/4885CES1 3552/4885AKR1B1 4476/4885
US-20230295215-A1 NOVEL MRNA 5'-END CAP ANALOGS MODIFIED WITHIN PHOSPHATE RESIDUES, RNA MOLECULE INCORPORATING THE SAME, USES THEREOF AND METHOD OF SYNTHESIZING RNA MOLECULE OR PEPTIDE RNGTT, RNMT, NSUN3 CES2 4066/4885CES1 3627/4885AKR1B1 4643/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.